1. Standardisation of Quality of Life Trials

   • Bert Spilker

   Guest Editorial 13 November 2012 Pages: 73 - 75

2. Health-Related Quality of Life in Pharmaceutical Evaluation

   • Donald L. Patrick

   Guest Editorial 13 November 2012 Pages: 76 - 78

3. Health Services Needs and Related Costs for HIV Care

   • Dennis P. Andrulis
   • Virginia Beers Weslowski

   Leading Article 13 November 2012 Pages: 79 - 83

4. Quality of Life Instruments in the Evaluation of New Drugs

   • Roman Jaeschke
   • Gordon H. Guyatt
   • Deborah Cook

   Review Article 13 November 2012 Pages: 84 - 93

5. Key Quality of Life Terms Used in the Evaluation of New Drugs

   • R. Jaeschke
   • G. H. Guyatt
   • D. Cook

   Guide Chart 13 November 2012 Pages: 94 - 94

6. Quality of Life Evaluation of Antihypertensive Drugs

   • Christopher J. Bulpitt
   • Astrid E. Fletcher

   Review Article 13 November 2012 Pages: 95 - 102

7. Pharmacoeconomics of Intravenous Drug Administration

   • S. E. Parker
   • P. G. Davey

   Review Article 13 November 2012 Pages: 103 - 115

8. A Comparison of the Safety, Timing and Cost-Effectiveness of Administering Antibiotics by Intravenous Bolus (Push) Versus Intravenous Piggyback (Slow Infusion) in Surgical Prophylaxis

   • James C. Garrelts
   • Dale F. Smith
   • Jerry D. Peterie

   Original Research Article 13 November 2012 Pages: 116 - 123

9. Simvastatin

   • Paul Chrisp
   • Nancy J. W. Lewis
   • Richard J. Milne

   Pharmacoeconomic Drug Evaluation 13 November 2012 Pages: 124 - 145

10. Efficacy and Cost-Effectiveness of Oral Ciprofloxacin

    • Steven L. Barriere

    Current Comment 13 November 2012 Pages: 146 - 147

11. Ethics in Health Economics

    • Donald C. Harrison

    Current Comment 13 November 2012 Pages: 147 - 148

12. Monitoring Tricyclic Antidepressant Therapy

    • Matthew V. Rudorfer

    Current Comment 13 November 2012 Pages: 148 - 150